Zylox-Tonbridge Medical Technology Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Zylox-Tonbridge Medical Technology has been growing earnings at an average annual rate of 16.5%, while the Medical Equipment industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 51.5% per year. Zylox-Tonbridge Medical Technology's return on equity is 0.8%, and it has net margins of 3.9%.
Belangrijke informatie
16.5%
Groei van de winst
27.7%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 13.7% |
| Inkomstengroei | 51.5% |
| Rendement op eigen vermogen | 0.8% |
| Nettomarge | 3.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02
Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Opbrengsten en kosten
Hoe Zylox-Tonbridge Medical Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 664 | 26 | 276 | 232 |
| 31 Mar 24 | 596 | -27 | 277 | 246 |
| 31 Dec 23 | 528 | -79 | 278 | 261 |
| 30 Sep 23 | 470 | -101 | 275 | 266 |
| 30 Jun 23 | 411 | -124 | 272 | 270 |
| 31 Mar 23 | 373 | -119 | 261 | 252 |
| 31 Dec 22 | 334 | -114 | 249 | 233 |
| 30 Sep 22 | 297 | -135 | 234 | 223 |
| 30 Jun 22 | 259 | -155 | 219 | 213 |
| 31 Mar 22 | 219 | -178 | 207 | 191 |
| 31 Dec 21 | 178 | -200 | 196 | 168 |
| 30 Sep 21 | 137 | -168 | 158 | 131 |
| 30 Jun 21 | 97 | -135 | 119 | 94 |
| 31 Mar 21 | 62 | -118 | 85 | 83 |
| 31 Dec 20 | 28 | -100 | 51 | 72 |
| 31 Dec 19 | 5 | -67 | 24 | 53 |
Kwaliteitswinsten: 2190 has a large one-off loss of CN¥19.3M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: 2190 became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2190 has become profitable over the past 5 years, growing earnings by 16.5% per year.
Versnelling van de groei: 2190 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: 2190 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.3%).
Rendement op eigen vermogen
Hoge ROE: 2190's Return on Equity (0.8%) is considered low.